MANGALAM34.88

Mangalam Drugs And Organics Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersBIOFILCHEMLASAVINEETLABORTINGLOBEKREBSBIOALPABALPHARMANATCAPSUQMcap ₹55.2 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations368.6318.2232.1289.8
Other Income0.10.50.80.3
Total Income368.7318.7232.9290.1
Expenses
+ Cost of Materials Consumed224.8170.6124.8158.4
+ Purchases of Stock-in-Trade10.718.30.00.0
+ Changes in Inventories9.1-21.532.131.6
+ Employee Benefit Expense39.140.633.842.7
+ Finance Costs13.914.916.219.9
+ Depreciation & Amortisation14.716.618.222.3
+ Other Expenses67.674.556.470.5
Total Expenses379.8313.9281.5345.4
EBITDA17.435.8-14.9-13.5
EBIT2.719.2-33.1-35.8
Profit
PBT before Exceptional Items-11.14.8-48.6-55.3
Pretax Income-11.14.8-48.6-55.3
+ Current Tax0.20.10.30.3
+ Deferred Tax-2.2-2.0-4.5-3.6
Tax Expense-2.0-1.9-4.2-3.3
Net Income-9.16.7-44.4-52.0
+ Net Income — Continuing Ops-9.16.7-44.4-52.0
+ Other Comprehensive Income-0.66.5-0.5-0.6
Total Comprehensive Income-9.613.2-44.9-52.6
Per Share
Basic EPS-5.734.25-28.05-32.88
Diluted EPS-5.734.25-28.05-32.88
Other Comprehensive Income — detail
+ Other Comprehensive Income6.5-0.5-0.6
+ Items NOT to be Reclassified to P&L-0.66.5
+ Tax on Items NOT to be Reclassified0.00.50.2
Per Share — as-filed variants
Basic EPS — Continuing Operations-5.734.25-28.05-32.88
Diluted EPS — Continuing Operations-5.734.25-28.05-32.88
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit124.1150.975.399.8
Gross Margin %33.6647.4132.4234.42
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)-11.14.8-48.6-55.3
Net Income Adj (tax-effected)-9.16.7-44.4-52.0
EPS Adj-5.734.25-28.05-32.88
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.00
Paid Up Equity Capital15.815.815.815.8
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.